LONDON – GW Pharma plc's Epidiolex is in the spotlight at the American Epilepsy annual conference in Washington this week as the company waits to hear if the FDA will accept the NDA in Dravet and Lennox-Gastaut syndromes and physicians report positive effects of the cannabis-derived drug in other forms of refractory epilepsy.